Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

26.48 -5.70 (-17.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
33 34 Next >
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
Exposures COVID-19
2 Big Stock Bets That Are Insiders Are Buying Now
Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy. 
Via InvestorPlace
CORRECTING and REPLACING CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Quick Take Technical Analysis: Cassava Sciences, Inc
Cassava Sciences, Inc (NASDAQ:SAVA) fell over 5% on Tuesda... 
Via Benzinga
CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
While Cassava Sciences Is a Risky Play, It Has Substantial Payoff Potential
Informed investors who can handle its high risk may want to take a look at speculative biotech play SAVA stock. 
Via InvestorPlace
Jim Cramer Weighs In On Carnival, Canadian Pacific Railway And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Fulgent Genetics, Inc. (NASDAQ: 
Via Benzinga
Should Investors Worry About the Federal Investigation of Cassava?
The investigation really isn't the underlying concern. 
Via The Motley Fool
Cassava Sciences Just Returned to the Buy Zone
There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares... 
Via Benzinga
Cassava Sciences Kickstarts Second Late-Stage Alzheimer's Trial With Simufilam
Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease. The second Phase 3 study is... 
Via Benzinga
3 Biotech Stocks That Have More Than Tripled so far This Year
But can they keep up the momentum? 
Via The Motley Fool
2 More Stocks Set to 2x… 5x… 10x in 2022
Finding 10x stocks is possible; it's simply a matter of knowing what patterns to look for. Here are a couple of strong contenders. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
61 Biggest Movers From Yesterday
Gainers Sono Group N.V. (NASDAQ: SEV) shares climbed 154.7% to close at $38.20 on Wednesday after the company priced its IPO at $15 per share. Braze, Inc. (NASDAQ: BRZE) jumped... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Mid-Afternoon Market Update: Dow Falls 200 Points; Rockwell Medical Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded down 0.58% to 35,930.89 while the NASDAQ fell 0.27% to 15,930.79. The S&P also fell, dropping 0.23% to 4,690.24. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
See Why Cassava Sciences Shares Are Falling On Wednesday?
The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA) manipulated data key to its case for... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Why Cassava Sciences Is Sliding Lower Today
Allegations of data manipulation that hammered the company -- and its stock price -- this summer won't be easily forgotten. 
Via The Motley Fool
Topics Regulatory Compliance
Exposures Legal Regulatory
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers EyePoint Pharmaceuticals (NASDAQ:EYP... 
Via Benzinga
Today’s Hot Penny Stocks: What’s Moving ZSAN, AVGR and CEI Higher Wednesday?
Today's hot penny stocks are catching the eyes of investors and we're diving into everything investors need to know about them on Wednesday! 
Via InvestorPlace
ROKU Stock Price Predictions: How Low One Analyst Thinks Roku Will Go
Roku (ROKU) stock price predictions aren't doing the shares any favors on Wednesday after one analyst put out a bearish take. 
Via InvestorPlace
Mid-Day Market Update: StoneCo Drops After Q3 Earnings; EyePoint Pharmaceuticals Shares Surge
Midway through trading Wednesday, the Dow traded down 0.51% to 35,958.22 while the NASDAQ rose 0.03% to 15,977.88. The S&P also fell, dropping 0.13% to 4,694.96. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
42 Stocks Moving In Wednesday's Mid-Day Session
Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares climbed... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
SAVA Stock Alert: The SEC Investigation That Has Cassava Sciences Cratering Today
Cassava Sciences (SAVA) stock is on the move Wednesday as investors react to reports of an SEC investigation over possible data manipulation. 
Via InvestorPlace
Topics Regulatory Compliance
Exposures Legal Regulatory
Cassava Sciences In Hot Water Again As Shorts Claim 'Extreme' Data Manipulation
In a filing, the short sellers claim the science backing Cassava's drug is impossible. 
Via Investor's Business Daily
Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc. (NASDAQ: 
Via Benzinga
NASDAQ:SAVA Long Term Investor Notice: Investigation of Potential Wrongdoing at Cassava Sciences, Inc.
San Diego, CA -- (SBWIRE) -- 11/15/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Cassava Sciences, Inc.. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
Cassava Pops As Cortexyme Dives — Why One Alzheimer's Stock Is 'Back On Track'
An analyst says Cassava is on track, but Cortexyme took another beating Thursday. 
Via Investor's Business Daily
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy... 
Via FinancialNewsMedia
Exposures COVID-19
7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside
Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. 
Via InvestorPlace
Cassava Sciences Needs Time and Data to Prove Itself Before You Buy
Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. 
Via InvestorPlace
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.